There are interests aside from control of the company. Equity is equity. If it is someone other than a BP that buys control, such as private equity, they would have little interest in trying to someday operate as a stand alone pharma company. So either a BP will buy the whole thing later or the private investor would buy the rest and try to sell the whole thing to a BP later. Even a BP investor could in the future want ADXS to be a wholly-owned subsidiary of sorts. All of these scenarios do happen. This is all conjecture, however. “Possible” doesn’t equal reality.
Market Data 
Markets 
AI
